Abstract: Since the release of the ‘‘Guidelines for the diagnosis and treatment of primary liver cancer (2024 edition)’’, there have been many high-level evidences in line with evidence-based medicine principles in the diagnosis, staging, and treatment of liver cancer worldwide, especially research results that are suitable for China’s national conditions have been published one after another. To this end, the department of Medical Administration, National Health Commission has organized multidisciplinary experts in the field of liver cancer nationwide, combined with the latest practices in clinical diagnosis, treatment, and research of liver cancer, to revise and update this guideline again, in order to better regulate the diagnosis and treatment of liver cancer, reflect the latest progress in liver cancer diagnosis and treatment, improve the overall survival rate of liver cancer patients, and further promote the implementation and achievement of the goal of increasing the overall cancer 5-year OS rate by 15% in the ‘‘Healthy China 2030’’ planning outline.